Artificial Intelligence in Medicine
Volume 46, Issue 2 , Pages 119-130 , June 2009

A decision aid for intensity-modulated radiation-therapy plan selection in prostate cancer based on a prognostic Bayesian network and a Markov model

  • Wade P. Smith

      Affiliations

    • 1959 NE Pacific St., Department of Radiation Oncology, Box 356043, University of Washington, Seattle, WA 98195-6043, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 206 598 8481; fax: +1 206 598 6218.
    • ,
  • Jason Doctor

      Affiliations

    • School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90033, United States
    • ,
  • Jürgen Meyer

      Affiliations

    • Department of Physics and Astronomy, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
    • ,
  • Ira J. Kalet

      Affiliations

    • 1959 NE Pacific St., Department of Radiation Oncology, Box 356043, University of Washington, Seattle, WA 98195-6043, United States
    • ,
  • Mark H. Phillips

      Affiliations

    • 1959 NE Pacific St., Department of Radiation Oncology, Box 356043, University of Washington, Seattle, WA 98195-6043, United States

Received 11 April 2008 ,Revised 5 September 2008 ,Accepted 1 December 2008.

References 

  1. Haas OC, Burnham KL, Mills JA. Optimization of beam orientation in radiotherapy using planar geometry. Phys Med Biol. 1998;43:2179–2193
  2. Phillips MH, Meyer J, Cho PS, Kalet IJ, Doctor JN. Bayesian decision making applied to IMRT. In:  Yi B,  Ahn S,  Choi E,  Ha S editor. Proceedings of the 14th international conference on computers in radiotherapy. Jeong Publishing; 2004;p. 108–111
  3. Meyer J, Phillips MH, Cho PS, Kalet I, Doctor JN. Application of influence diagrams to prostate intensity-modulated radiation therapy plan selection. Phys Med Biol. 2004;49:1637–1653
  4. Perez CA. Prostate. In:  Perez CA,  Brady LW,  Halperin EC,  Schmidt-Ulrich RK editor. Principles and practices of radiation oncology. 4th ed. Philadelphia, PA: Lippincott-Raven Publishers; 2004;p. 1692–1762
  5. A.S. for Therapeutic Radiology, O.C. Panel, Consensus statement: guidelines for PSA following radiation therapy, Int J Radiat Oncol Biol Phys 37;1997:1035–41.
  6. Jensen FV, Nielson TD. Bayesian networks and decision graphs. New York: Springer-Verlag; 2007;
  7. Cowell RG, Dawid AP, Lauritzen AL, Spiegelhalter DJ. Probabilistic networks and expert systems. New York: Springer; 1999;
  8. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095–1101
  9. Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001;92:1281–1287
  10. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys. 1997;24:103–110
  11. Wang JZ, Li XA. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. Med Phys. 2003;30:34–40
  12. Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005;23:826
  13. Vicini FA, Kestin LL, Martinez AA. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer. 2000;88:2305–2318
  14. Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;15:953–962
  15. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 1985;8:13–S19
  16. Lyman JT, Wolbarst AB. Optimization of radiation therapy. III. A method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys. 1987;13:103–109
  17. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys. 1989;16:1623–1630
  18. Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study. Radiother Oncol. 2004;73:21–32
  19. Peeters ST, Hoogeman MS, Heemsbergen AA, Hart WD, Koper PC, Lebesque JV. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys. 2006;66:11–19
  20. Söhn M, Yan D, Liang J, Meldolesi E, Vargas C, Alber M. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys. 2007;67:1066–1073
  21. Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1059–1065
  22. Beck JR, Pauker SB. The Markov process in medical prognosis. Med Decis Making. 1983;3:419–458
  23. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–338
  24. Hunink M, Glasziou P. Decision making in health and medicine. Cambridge: Cambridge University Press; 2001;
  25. Period life table. http://www.ssa.gov/oact/stats/table4c6.html; 2004 [accessed 4.09.08].
  26. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43:347–355
  27. Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, et al. Whole-pelvis, mini-pelvis, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the radiation. Int J Radiat Oncol Biol Phys. 2006;66(3):647–653
  28. Karlsdóttir A, Muren LP, Wentzel-Larsen T, Dahl O. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys. 2008;70:1478–1486
  29. Sommers BD, Beard CJ, D’Amico AV, Dahl D, Kaplan I, Richie JP, et al. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer. 2007;110:2210–2217
  30. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase iii trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–2504
  31. Miften MM, Das SK, Su M, Marks LB. A dose-volume-based tool for evaluating and ranking IMRT treatment plans. J Appl Clin Med Phys. 2004;5:1–14
  32. Meyer RR, Zhang ZH, Goadrich L, Nazareth DP, Shi L, D’Souza WD. A multiplan treatment-planning framework: a paradigm shift for intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1178–1189
  33. Jain NL, Kahn MG, Drzymala RE, Emami BE, Purdy JA. Objective evaluation of 3-d radiation treatment plans: a decision-analytic tool incorporating treatment preferences of radiation oncologists. Int J Radiat Oncol Biol Phys. 1993;26:321–333
  34. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993;269:2650
  35. Bhatnagar V, Stewart ST, Bonney WW, Kaplan RM. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time. Urology. 2004;63:103–109
  36. Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:408–415
  37. Konski A, Speier W, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol. 2007;25:3603–3608
  38. Lucas PJ, Boot H, Taal BG. Computer-based decision support in the management of primary gastric non-Hodgkin lymphoma. Methods Inform Med. 1998;3:206–219
  39. Galán SF, Aguado F, Díez FJ, Mira J. NasoNet modeling the spread of nasopharyngeal cancer with networks of probabilistic events in discrete time. Artif Intell Med. 2002;25:247–264
  40. Rouprêt M, Hupertan V, Yates D, Comperat E, Catto J, Meuth M, et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int. 2008;101(11):1448–1452
  41. Lucas PJ, van der Gaag LC, Abu-Hanna A. Bayesian networks in biomedicine and health-care. Artif Intell Med. 2004;30:201–214
  42. Verduijn M, Peek N, Rosseel PM, de Jonge E, de Mol BA. Prognostic Bayesian networks I: rationale, learning procedure, and clinical use. J Biomed Inform. 2007;40(6):609–618
  43. Pauker SG, Wong JB. The influence of influence diagrams in medicine. Decis Anal. 2005;2:238

PII: S0933-3657(08)00184-X

doi: 10.1016/j.artmed.2008.12.002

Artificial Intelligence in Medicine
Volume 46, Issue 2 , Pages 119-130 , June 2009

Article Tools

* Image Usage & Resolution